- Trial phase
- Filed/Under Review (EU); Phase 3 completed (US pending submission)
- Time to market
- EU approval (European Commission decision) expected within weeks (by late November 2026). US BLA submission planned for 2H 2026, with FDA review likely extending into 2027.
- Why 3/10
- The next hard catalyst is the European Commission's final marketing authorization decision on VaxRabeo (SP0087), expected within approximately 67 days of the September 17, 2026 CHMP positive opinion (i.e., by late November 2026). Sanofi is a large-cap diversified pharma; this single vaccine is a small part of a 61-project pipeline, so even a positive EC decision will not materially move SNY's share price.
The next hard catalyst is the European Commission's final decision on VaxRabeo (SP0087), expected within weeks after the September 17 CHMP positive opinion. A positive decision would enable EU launch and potentially accelerate Sanofi's US BLA submission, which was planned for 2H 2026. For a company of Sanofi's scale, this is a pipeline maintenance event rather than a stock-moving binary.
Price Chart
Executive Summary
SP0087 is Sanofi's next-generation, serum-free, inactivated rabies vaccine (branded VaxRabeo in the EU). It completed Phase 3 trials showing non-inferior immunogenicity versus existing licensed rabies vaccines. On September 17, 2026, the EMA's CHMP adopted a positive opinion recommending EU marketing authorization for all age groups in both pre-exposure and post-exposure prophylaxis. The European Commission's final decision is expected within approximately 67 days (by late November 2026). Sanofi has also signaled intent to submit a US BLA in the second half of 2026. For a company of Sanofi's size and diversification, SP0087 is a modest pipeline asset in a roughly $1.4 billion global rabies vaccine market.
How It Works
SP0087 is an inactivated (killed-virus) rabies vaccine. It uses rabies virus grown in Vero cells (a standard cell line for vaccine production), then purified and inactivated so it cannot cause disease. When injected, it trains the immune system to produce antibodies against the rabies virus. It is formulated without serum (animal-derived components), which is a manufacturing improvement over older rabies vaccines. It is designed for both pre-exposure prevention (for travelers, lab workers) and post-exposure prophylaxis (after a potential rabies exposure, given alongside rabies immunoglobulin).
Trial Status
Multiple Phase 3 trials completed demonstrating non-inferior immunogenicity and safety versus licensed rabies vaccines (Verorab, Imovax, HDCV). The pivotal Phase 3 study (NCT04127786) read out positively in mid-2025. EU marketing application was filed in April 2026 and received a positive CHMP opinion on September 17, 2026.
The Two-Sided Case
Upcoming Catalysts
- European Commission final marketing authorization decision on VaxRabeo (SP0087), expected by late November 2026
- Potential US BLA submission to FDA, planned for 2H 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report